Repotrectinib in <i>ROS1</i> Fusion–Positive Non–Small-Cell Lung Cancer-Reference-Cited by-全球学者库

Repotrectinib in ROS1 Fusion–Positive Non–Small-Cell Lung Cancer

Published:2024-01-11 Issue:2 Volume:390 Page:118-131
ISSN:0028-4793
Container-title:New England Journal of Medicine
language:en
Short-container-title:N Engl J Med

Author:

Drilon Alexander¹,Camidge D. Ross¹,Lin Jessica J.¹,Kim Sang-We¹,Solomon Benjamin J.¹,Dziadziuszko Rafal¹,Besse Benjamin¹,Goto Koichi¹,de Langen Adrianus Johannes¹,Wolf Jürgen¹,Lee Ki Hyeong¹,Popat Sanjay¹,Springfeld Christoph¹,Nagasaka Misako¹,Felip Enriqueta¹,Yang Nong¹,Velcheti Vamsidhar¹,Lu Shun¹,Kao Steven¹,Dooms Christophe¹,Krebs Matthew G.¹,Yao Wenxiu¹,Beg Muhammad Shaalan¹,Hu Xiufeng¹,Moro-Sibilot Denis¹,Cheema Parneet¹,Stopatschinskaja Shanna¹,Mehta Minal¹,Trone Denise¹,Graber Armin¹,Sims Gregory¹,Yuan Yong¹,Cho Byoung Chul¹

Affiliation:

1. From Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College (A.D.) and the NYU Perlmutter Cancer Center (V.V.) — all in New York; the University of Colorado, Anschutz Medical Campus, Aurora (D.R.C.); Massachusetts General Hospital, Harvard Medical School, Boston (J.J.L.); Asan Medical Center (S.-W.K.) and Yonsei Cancer Center, Yonsei University College of Medicine (B.C.C.), Seoul, and Chungbuk National University Hospital, Cheongju-si (K.H.L.) — all in South Korea; the Peter MacCallum...

Funder

Manchester Biomedical Research Centre

National Cancer Institute

Bristol-Myers Squibb

Publisher

Massachusetts Medical Society

Subject

General Medicine

Link

http://www.nejm.org/doi/pdf/10.1056/NEJMoa2302299

Reference19 articles.

1. ROS1-dependent cancers — biology, diagnostics and therapeutics

2. Patterns of Metastatic Spread and Mechanisms of Resistance to Crizotinib in ROS1-Positive Non–Small-Cell Lung Cancer

3. Pre‐ and post‐treatment blood‐based genomic landscape of patients with ROS1 or NTRK fusion‐positive solid tumours treated with entrectinib

4. Spectrum of Mechanisms of Resistance to Crizotinib and Lorlatinib in ROS1 Fusion–Positive Lung Cancer

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Repotrectinib effective in ROS1-fusion-positive NSCLC;Nature Reviews Clinical Oncology;2024-01-26

2. Comprehensive Review of ROS1 Tyrosine Kinase Inhibitors-Classified by Structural Designs and Mutation Spectrum (Solvent Front Mutation [G2032R] and Central β-Sheet 6 [Cβ6] Mutation [L2086F]);Journal of Thoracic Oncology;2023-12